Neuroscience analysis technology specialist Ixico has been selected by an unnamed, “leading” global pharmaceutical company and new client, it announced on Friday, to provide MRI imaging services for an early-phase clinical trial in multiple system atrophy.
The AIM-traded firm said it had signed a start-up agreement with the client, which was expected to extend to a contract value of about £0.6m early in 2023.
It said the trial was expected to last for two years.
“Since its inception, Ixico has built an extensive portfolio of proprietary imaging data management and analysis technologies for investigation of neurological disorders across the entire drug development lifecycle, from phase one through to commercialisation,” the board said in its statement.
At 1430 GMT, shares in Ixico were up 5.49% at 26.9p.
Reporting by Josh White for Sharecast.com.
